This study uses data from a trial comparing clopidogrel and aspirin vs aspirin alone for preventing stroke in patients with TIA to investigate associations between CYP2C19 status and effects of the drugs.
This secondary analysis of data from the Dual Antiplatelet Therapy (DAPT) trial describes development of a risk prediction tool to identify benefits and harms of continuing thienopyridine therapy after an initial year of treatment following percutaneous coronary intervention.
A 50-year-old man reported experiencing blurry vision for 5 months. He has a BMI of 30.6 and blood pressure of 160/102 mm Hg. Dilated retinal examination showed arteriolar narrowing, microaneurysms, intraretinal hemorrhaging, and cotton-wool spots. What would you do next?
In this cohort study, there was no survival difference at 15 years among older patients who underwent mechanical prosthetic vs bioprosthetic mitral replacement.
This randomized superiority trial in China found that among patients undergoing PCI, bivalirudin was associated with reduced adverse effects compared with heparin alone and heparin plus tirofiban.
This analysis of data from Danish administrative registries reports that among patients receiving antithrombotic therapy after myocardial infarction, use of nonsteroidal anti-inflammatory drugs was associated with increased risk of bleeding and thrombotic events.
This cohort study showed that in routine care, fondaparinux was associated with lower rates of death and major bleeding among Swedish patients with non–ST-segment myocardial infarction.
This randomized trial reports that among patients with severe trauma and major bleeding, early administration of plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio did not result in significant differences in mortality at 24 hours or at 30 days.
This retrospective cohort analysis quantifies survival and major morbidity in patients aged 50 to 69 years receiving bioprosthetic vs mechanical aortic valve replacement.
This systematic review found that low-molecular-weight heparin combined with vitamin K antagonist did not differ in safety or efficacy from most treatment strategies; however, rivaroxaban and apixaban were associated with the lowest risk of bleeding.
Chatterjee and coauthors performed a meta-analysis to determine benefits and risks associated with thrombolytic therapy vs anticoagulation in acute pulmonary embolism, including the subset of hemodynamically stable patients with right ventricular dysfunction. In an Editorial, Beckman discusses how to assess the net clinical benefit of thrombolysis for patients with pulmonary embolism.
Carrero and coauthors study outcomes associated with warfarin treatment in relation to kidney function among 24 317 patients after myocardial infarction (MI) in Sweden from 2003 to 2010. In an Editorial, Winkelmayer discusses whether these findings should change clinical practice in caring for patients with atrial fibrillation worldwide.
Sherwood and coauthors conducted a retrospective cohort study of 2 258 711 patient visits in the CathPCI Registry to determine current patterns of blood transfusion among patients undergoing percutaneous coronary intervention (PCI) and the association of transfusion with adverse cardiac outcomes.
In a review of the literature on optimal medical therapy after percutaneous coronary intervention
(PCI), Brilakis and coauthors determined that dual antiplatelet therapy remains the standard of
care, with adjustments as needed for patients at high risk for bleeding and those who have coronary